CV Sciences Inc (CVSI)

[super_trades]

Wolf, CVSI R&D is split between development of their nicotine drug and their CBD segment. Page 16 of the 10Q. So 600k on CBD R&D is something not much at all.

Research and development (“R&D”) expense increased to $1.7 million in the second quarter of 2019 compared to $0.4 million in the second quarter of 2018. The increase of $1.3 million or 282% is related to additional R&D expenses for our specialty pharmaceutical segment of $0.7 million and for our consumer products segment of $0.6 million. The increase in our specialty pharmaceutical segment is mostly related to preclinical work, development cost associated with our active pharmaceutical ingredient ("API"), and expenses paid to outside consultants. The additional R&D expense in our consumer products segment is mostly related to additional personnel cost, cost for clinical trials, and cost for outside services for our new consumer product developments.